The feasibility and safety of obtaining research kidney biopsy cores in patients with diabetes an interim analysis of the trident study

TRIDENT Study Investigators

doi:10.2215/CJN.13061019

The feasibility and safety of obtaining research kidney biopsy cores in patients with diabetes an interim analysis of the trident study

TRIDENT Study Investigators

Producción científica: Letter › revisión exhaustiva

Idioma original	English (US)
Páginas (desde-hasta)	1024-1026
Número de páginas	3
Publicación	Clinical Journal of the American Society of Nephrology
Volumen	15
N.º	7
DOI	https://doi.org/10.2215/CJN.13061019
Estado	Published - jul 2020

ASJC Scopus subject areas

Epidemiology
Critical Care and Intensive Care Medicine
Nephrology
Transplantation

Acceder al documento

10.2215/CJN.13061019

Otros archivos y enlaces

Citar esto

@article{6d82d72be7a14398a0589be57a47e5e3,

title = "The feasibility and safety of obtaining research kidney biopsy cores in patients with diabetes an interim analysis of the trident study",

author = "{TRIDENT Study Investigators} and Hogan, {Jonathan J.} and Owen, {Jonathan G.} and Blady, {Shira J.} and Salem Almaani and Avasare, {Rupali S.} and Shweta Bansal and Oliver Lenz and Luciano, {Randy L.} and Parikh, {Samir V.} and Ross, {Michael J.} and Deep Sharma and Harold Szerlip and Shikha Wadhwani and Townsend, {Raymond R.} and Palmer, {Matthew B.} and Katalin Susztak and Mottl, {Amy K.}",

note = "Funding Information: Dr. S. Almaani reports personal fees from Aurinia, outside the submitted work. Ms. S.J. Blady reports other from University of Pennsylvania, during the conduct of the study. Dr. J.J. Hogan reports grantsfromBoehringerIngelheim,GileadSciences,GlaxoSmithKline and Regeneron Pharmaceuticals, during the conduct of the study; personal fees from Retrophin, personal fees from Dimerix, personal fees from Zyversa, personal fees from GSK, other from Calliditas, other from Omeros, other from Achillion, outside the submitted work. Dr. A.K. Mottl received other funding from Duke Clinical Research Institute, Pfizer, Aurinia, and Calliditas, outside the submitted work. Dr. S.V. Parikh reports personal fees from AstraZeneca, Aurinia Pharmaceuticals, and Bristol Myers Squib, and grants from Funding Information: the NIH, outside the submitted work, and grants from Aurinia Pharmaceuticals, EMD-Serono, and Mallinckrodt, outside the submitted work. Dr. S. Wadhwani reports personal fees from Bristol-Myers Squibb, Alexion Pharmaceuticals, and the Lupus Foundation of America, and grants from the NIH, outside the submitted work. Dr. K. Susztak reports personal fees from Janssen, Novo Nordisk, Maze, and Jnana Therapeutics, Boerhinger Ingelheim Japan, Kiowa Kirin. Dr. O. Lenz reports that he is president and majority shareholder of L & F Health LLC, outside of submitted work. Dr. D. Sharma reports grant funding from GlaxoSmithKlein, outside the submitted work. Dr. H. Szerlip reports personal fees from AstraZeneca, Retrophin, Lajolla and Janssen, outside the submitted work, grants from University of Pennsylvania, during the conduct of the study, and grants from Retrophin, Aurinia, Omeros, Bayer, Akebia, AstraZeneca, outside the submitted work. All remaining authors have nothing to disclose. Funding Information: The Transforming Research in Diabetic Nephropathy study is supported by Boehringer Ingelheim, GlaxoSmithKline, Regeneron Pharmaceuticals, and Gilead Sciences, Inc.",

year = "2020",

month = jul,

doi = "10.2215/CJN.13061019",

language = "English (US)",

volume = "15",

pages = "1024--1026",

journal = "Clinical Journal of the American Society of Nephrology",

issn = "1555-9041",

publisher = "Lippincott Williams and Wilkins",

number = "7",

}

TY - JOUR

T1 - The feasibility and safety of obtaining research kidney biopsy cores in patients with diabetes an interim analysis of the trident study

AU - TRIDENT Study Investigators

AU - Hogan, Jonathan J.

AU - Owen, Jonathan G.

AU - Blady, Shira J.

AU - Almaani, Salem

AU - Avasare, Rupali S.

AU - Bansal, Shweta

AU - Lenz, Oliver

AU - Luciano, Randy L.

AU - Parikh, Samir V.

AU - Ross, Michael J.

AU - Sharma, Deep

AU - Szerlip, Harold

AU - Wadhwani, Shikha

AU - Townsend, Raymond R.

AU - Palmer, Matthew B.

AU - Susztak, Katalin

AU - Mottl, Amy K.

N1 - Funding Information: Dr. S. Almaani reports personal fees from Aurinia, outside the submitted work. Ms. S.J. Blady reports other from University of Pennsylvania, during the conduct of the study. Dr. J.J. Hogan reports grantsfromBoehringerIngelheim,GileadSciences,GlaxoSmithKline and Regeneron Pharmaceuticals, during the conduct of the study; personal fees from Retrophin, personal fees from Dimerix, personal fees from Zyversa, personal fees from GSK, other from Calliditas, other from Omeros, other from Achillion, outside the submitted work. Dr. A.K. Mottl received other funding from Duke Clinical Research Institute, Pfizer, Aurinia, and Calliditas, outside the submitted work. Dr. S.V. Parikh reports personal fees from AstraZeneca, Aurinia Pharmaceuticals, and Bristol Myers Squib, and grants from Funding Information: the NIH, outside the submitted work, and grants from Aurinia Pharmaceuticals, EMD-Serono, and Mallinckrodt, outside the submitted work. Dr. S. Wadhwani reports personal fees from Bristol-Myers Squibb, Alexion Pharmaceuticals, and the Lupus Foundation of America, and grants from the NIH, outside the submitted work. Dr. K. Susztak reports personal fees from Janssen, Novo Nordisk, Maze, and Jnana Therapeutics, Boerhinger Ingelheim Japan, Kiowa Kirin. Dr. O. Lenz reports that he is president and majority shareholder of L & F Health LLC, outside of submitted work. Dr. D. Sharma reports grant funding from GlaxoSmithKlein, outside the submitted work. Dr. H. Szerlip reports personal fees from AstraZeneca, Retrophin, Lajolla and Janssen, outside the submitted work, grants from University of Pennsylvania, during the conduct of the study, and grants from Retrophin, Aurinia, Omeros, Bayer, Akebia, AstraZeneca, outside the submitted work. All remaining authors have nothing to disclose. Funding Information: The Transforming Research in Diabetic Nephropathy study is supported by Boehringer Ingelheim, GlaxoSmithKline, Regeneron Pharmaceuticals, and Gilead Sciences, Inc.

PY - 2020/7

Y1 - 2020/7

UR - http://www.scopus.com/inward/record.url?scp=85087552504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087552504&partnerID=8YFLogxK

U2 - 10.2215/CJN.13061019

DO - 10.2215/CJN.13061019

M3 - Letter

C2 - 32341009

AN - SCOPUS:85087552504

SN - 1555-9041

VL - 15

SP - 1024

EP - 1026

JO - Clinical Journal of the American Society of Nephrology

JF - Clinical Journal of the American Society of Nephrology

IS - 7

ER -